| product Name |
Afatinib Dimaleate |
| Synonyms |
BIBW2992 DiMaleate; BIBW2992-MA2 |
| Molecular Formula |
C32H33ClFN5O11 |
| Molecular Weight |
718.08 |
| CAS Registry Number |
850140-73-7 |
| Molecular Structure |
|
| Description |
Afatinib dimaleate (Tovok; BIBW2992; Gilotrif) is a salt form of Afatinib. Afatinib is a second-generation, orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases. |
| Uses |
Afatinib Dimaleate is a salt of Afatinib {BIBW 2992), an aminocrotonylamino-substituted quinazoline derivative used for treating cancer and diseases of the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder. An anilino-quinazoline that irreversibly inhibits EGFR and HER2 kinase activity. |
| Definition |
ChEBI: Afatinib dimaleate is a maleate salt obtained by combining afatinib with two molar equivalents of maleic acid. Used for the first-line treatment of patients with metastatic non-small cell lung cancer. It has a role as a tyrosine kinase inhibitor and an antineoplastic agent. It contains an afatinib. |
Reviews
There are no reviews yet.